Navigation Links
Novogen Launches Joint Venture Aimed At Developing Drugs to Fight Ovarian Cancer
Date:11/6/2013

SYDNEY, Nov. 6, 2013 /PRNewswire/ -- Novogen Limited (Australian Securities Exchange: NRT and NASDAQ: NVGN), an Australian biotechnology company dedicated to developing drugs that provide long-term remission through the successful control of cancer stem cells, today announced a joint venture with Yale University dedicated to developing personalized approaches to chemotherapy to fight ovarian cancer.

The joint venture, which will be based near Yale's campus in New Haven, CT, will be known as CanTx, Inc. Novogen will own 85% of the new company and Novogen CEO Graham Kelly, PhD will be CEOoft the new joint venture as well. The CanTx Board will be comprised of directors representing both Novogen and Yale.

CanTx will assume responsibility for advancing Novogen's super-benzopyran drug technology into the clinic for the treatment of ovarian cancer. CanTx's first development candidate, designed to seek out cancer cells and deliver a payload of a Novogen drug that has been shown to be highly cytotoxic against ovarian cancer cells including ovarian cancer stem cells, is expected to enter clinical studies in 2014. The investigational product will be administered intra-peritoneally to women with ovarian cancer.

"There have been no new therapies for ovarian cancer in the last 30 years and a fresh approach is urgently needed," said Gil Mor, M.D., Ph.D., Professor of Obstetrics and Gynecology and Reproductive Science at Yale University School of Medicine. "Current chemotherapy unfortunately only does half the job. It is reasonably effective at killing the predominant somatic cancer cells, but by not killing the source of the cancer, the cancer stem cells, the cancer is highly likely to recur."

Dr. Mor, who will co-lead clinical development efforts for CanTx, is
'/>"/>

SOURCE Novogen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. As Released on 30 December, 2011: Novogen Modifies ADR Program and Makes Further Investment Into Marshall Edwards
2. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
3. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
4. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
5. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
6. Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services
7. Neogen Launches Fully Quantitative Lateral Flow Test for DON
8. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
9. iHealth Lab Launches Personalized Web Portal to Store Your Vitals
10. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
11. Upsher-Smith Launches B-Nexa® Prescription Prenatal Vitamin With B Vitamins and Ginger for Nausea and Vomiting of Pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... SunTrust Robinson Humphrey (STRH) today announced the ... research team in biotechnology and oilfield services.  ... demonstrates our commitment to providing our valued institutional ... decision making," said Biff Woodruff , Head ... significant investments in differentiated content at a time ...
(Date:8/28/2014)... Vt. (PRWEB) August 28, 2014 ... testing around the world is available from Strategic ... diagnostics companies. “ Industrial Microbiology Market Review, Fourth ... Industrial Market ” (IMMR—4) tracks and compares microbiology ... in North America, Europe and Asia, and forecasts ...
(Date:8/27/2014)... August 27, 2014 Varian Medical Systems ... its current Salt Lake City manufacturing facility and allow ... Utah to ultimately create 1,000 new full time jobs ... , “Utah is home to hardworking people with immense ... credited with Varian’s success in the manufacturing of our ...
(Date:8/27/2014)... , Aug. 27, 2014   MSC , a ... safety, today announced the appointment of Mary Beth ... With 28 years of experience preparing companies for rapid ... as Executive Vice President of Corporate Development and Healthcare. ... improvement business , as well as corporate strategy and ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3MSC names Mary Beth Loesch President and CEO 2
... activity (regenerative potential) of stem cells and accelerates ... MaxCyte announces today the introduction of its ... Stem Cell Summit to be held in New ... is a validated, scalable technology for customizing the ...
... Feb. 17 Human Genome Sciences, Inc. (Nasdaq: ... GSK ) has initiated a Phase 3 clinical ... of Syncria (R) (albiglutide) in the long-term treatment ... HGS will receive a $9 million milestone payment in ...
... VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced ... (NDA) with the U.S. Food and Drug Administration (FDA) ... a single agent for remission induction treatment for patients ... novo poor-risk acute myeloid leukemia (AML). The ...
Cached Biology Technology:MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 2MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 2Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 4Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 2Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 3Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 4
(Date:8/29/2014)... The rise of the Tibetan plateau -- the largest ... important for both its profound effect on climate and ... in GSA Bulletin , Katharine Huntington and colleagues ... -- using modern and fossil snail shells to investigate ... Tibet. , Views range widely on the timing ...
(Date:8/28/2014)... This news release is available in German . ... fresh water fish, owes its name to a striking pattern ... cell types, black cells, reflective silvery cells, and yellow cells ... fish and arrange as a multilayered mosaic to compose the ... all three cell types have to interact to form proper ...
(Date:8/28/2014)... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for the Genetics Society of America,s 27th ... October 3, 2014 in Pacific Grove, California. ... entry of students, post doctorates and scientists from ... science community and to encourage the participation of ...
Breaking Biology News(10 mins):Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
... bumblebee species from an ecosystem and the impact is ... seeds, a new study finds. The study, to ... Academy of Sciences , focused on the interactions between ... results show how reduced competition among pollinators disrupts floral ...
... , July 26, 2013 /PRNewswire-iReach/ -- TestoMeds is ... discounts online for those seeking testosterone or progesterone ... deficiencies. (Photo: http://photos.prnewswire.com/prnh/20130726/MN54049 ) ... testosterone replacement creams – Androforte, Androfeme, and ...
... relevant information while ignoring distractions is a core brain ... "noise," we could not effectively interact with our environment. ... cellular mechanisms responsible for the effects of attention have ... in the journal Nature , researchers from Dartmouth,s ...
Cached Biology News:Bees 'betray' their flowers when pollinator species decline 2Bees 'betray' their flowers when pollinator species decline 3Bees 'betray' their flowers when pollinator species decline 4Androforte for Low T is Better Absorbed and More Economical than Androgel or Testim! 2Androforte for Low T is Better Absorbed and More Economical than Androgel or Testim! 3Androforte for Low T is Better Absorbed and More Economical than Androgel or Testim! 4